Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) ...

Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025Strong financial position with cash and cash equ ...

-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash position of $ ...

MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights Generated total revenue of $13.6 million, representing growth of 7% year-over-year and 14% sequential growth versus the first qu ...

Core Viewpoint - Pixelworks, Inc. reported its financial results for the second quarter of 2025, showing a sequential revenue increase driven by seasonal growth in product shipments, while also highlighting ongoing strategic opportunities and collaborations in the mobile sector [1][4][17]. Financial Performance - Revenue for Q2 2025 was $8.3 million, up from $7.1 million in Q1 2025 but down from $8.5 million in Q2 2024, indicating a 16% sequential increase [4][17]. - GAAP gross profit margin for Q2 2025 was 45.8%, compared to 48.7% in Q1 2025 and 50.7% in Q2 2024 [5][23]. - Non-GAAP gross profit margin for Q2 2025 was 46.0%, down from 49.9% in Q1 2025 and 51.0% in Q2 2024 [6][23]. - The company recorded a GAAP net loss of $6.7 million, or ($1.27) per share, an improvement from a loss of $7.8 million, or ($1.54) per share in Q1 2025, and a loss of $10.1 million, or ($2.09) per share in Q2 2024 [7][8][21]. - Non-GAAP net loss for Q2 2025 was $5.3 million, or ($1.00) per share, compared to a loss of $6.5 million, or ($1.30) per share in Q1 2025, and a loss of $7.7 million, or ($1.60) per share in Q2 2024 [8][21]. Business Developments - The company is focusing on advancing market opportunities through its Shanghai-based subsidiary, with increased interest in collaborations for mobile visual processors and ASIC design services [3][17]. - Pixelworks is experiencing momentum in its TrueCut Motion business, securing new titles and expanding partnerships in content and distribution [3][17]. - The Shanghai subsidiary received approximately $1.6 million in cash subsidies as part of China's "Little Giant" program [17]. Operational Efficiency - GAAP operating expenses for Q2 2025 were $11.1 million, down from $11.5 million in Q1 2025 and $15.1 million in Q2 2024 [5][6]. - Non-GAAP operating expenses for Q2 2025 were $9.7 million, compared to $10.4 million in Q1 2025 and $12.8 million in Q2 2024 [6][21]. - Adjusted EBITDA for Q2 2025 was a negative $4.3 million, an improvement from a negative $5.8 million in Q1 2025 and a negative $7.0 million in Q2 2024 [10][24].

Core Insights - Theravance Biopharma reported strong execution in Q2 2025, driven by commercial growth and operational discipline, with significant progress on ampreloxetine and a milestone payment from YUPELRI's approval in China [2][5][10] Financial Performance - Total revenue for Q2 2025 was $26.2 million, comprising $18.7 million from Viatris collaboration and $7.5 million from licensing revenue [10] - Viatris collaboration revenue increased by 31% year-over-year, amounting to $18.7 million in Q2 2025 [10] - Net income for Q2 2025 was $54.8 million, a significant improvement from a net loss of $16.5 million in Q2 2024 [10][30] - Non-GAAP net loss from operations was $4.2 million in Q2 2025, compared to a loss of $6.3 million in the same period in 2024 [10][30] Operational Highlights - YUPELRI net sales reached $66.3 million in Q2 2025, reflecting a 22% increase year-over-year [5][6] - The pivotal Phase 3 CYPRESS study for ampreloxetine is on track for enrollment completion by late summer 2025, with top-line data expected approximately six months later [5][10] - The company completed the sale of its TRELEGY royalty interest to GSK for $225 million, enhancing its financial position [5][10] Cash Position and Guidance - As of June 30, 2025, the company had $339 million in cash and no debt, indicating a strong balance sheet [5][10] - The company anticipates full-year 2025 global net sales to exceed $3.4 billion, with a milestone of $50 million from Royalty Pharma expected to be triggered [5][10] Strategic Focus - The company is focused on disciplined capital allocation and returning excess cash to shareholders, with ongoing evaluations of strategic alternatives to enhance shareholder value [7][10]

SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK) ("QuickLogic" or the "Company"), a developer of embedded FPGA (eFPGA) IP, ruggedized FPGAs, and Endpoint AI solutions, today announced its financial results for the fiscal second quarter that ended June 29, 2025.Recent Highlights Signed a new, revenue-generating eFPGA Hard IP License contract for a customer's Intel 18A test chip Awarded a feasibility contract for a very high-density eFPGA IP core Announced Aurora PRO FPGA ...

– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:3 ...

Company Reaffirms FY 2025 Revenue Guidance Range of $111.0 Million to $113.0 Million, Representing 10% Year-Over-Year Growth at the Midpoint Company Reaffirms Expectation for ARR1 to Increase from $95.6 Million at the Beginning of 2025 to Approximately $110.0 Million at the Beginning of 2026 FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, today reported financial results for the second quarter ended June 30, 2025. Second Quar ...

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.Plains All American Pipeline, L.P. (NYSE: PAA ) is a midstream MLP with a more than $12 billion market cap and a high single-digit dividend yield. The com ...